- Home
- TXO vs JANX Comparison
TXO vs JANX Comparison
Compare TXO & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TXO | JANX |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 681.7M | 790.3M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TXO | JANX |
|---|---|---|
| Price | $12.75 | $13.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $20.50 | ★ $53.60 |
| AVG Volume (30 Days) | 199.9K | ★ 739.0K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 13.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $401,012,000.00 | $10,000,000.00 |
| Revenue This Year | $15.64 | N/A |
| Revenue Next Year | N/A | $209.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.80 | N/A |
| 52 Week Low | $10.12 | $12.12 |
| 52 Week High | $19.99 | $35.34 |
Technical Indicators
Market Signals| Indicator | TXO | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 49.46 |
| Support Level | $12.50 | $13.80 |
| Resistance Level | $12.94 | $14.46 |
| Average True Range (ATR) | 0.34 | 0.57 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 61.32 | 57.05 |
Price Performance
Historical ComparisonAbout TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America. Its operations focus on enhancing the development and operation of producing properties through its concentration on efficiency and optimizing exploitation of current wells.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.